{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:22:20Z","timestamp":1771989740654,"version":"3.50.1"},"reference-count":37,"publisher":"Portland Press Ltd.","issue":"7","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>High-on treatment platelet reactivity (HTPR) leads to more prevalence of thrombotic event in patients undergoing percutaneous coronary interventions (PCI). Dual antiplatelet therapy with aspirin in addition to one P2Y12 inhibitor is commonly administrated to reduce HTPR. However, \u2018one size fits all\u2019 antiplatelet strategy is widely implemented due to lacking benefits with tailored strategy. One reason for the failure of tailored treatment might be less specificity of the current indicators for HTPR. Therefore, searching for specific indicators for HTPR is critical. Thromboelastograph with platelet mapping (TEGpm) assay has been explored for identifying HTRP. Variables of TEGpm assay, including maximum amplitude (MA) induced by thrombin (MAthrombin), R time, platelet aggregation rate induced by ADP (TEGaradp) and MA induced by ADP (MAadp) have been demonstrated to be able to identify HTPR in post-PCI patients. However, these variables for HTPR might be less specific. Thus, in the present study, a novel variable nMAadp was derived by removing fibrin contribution from MAadp and analyzed for its usefulness in determining HTPR. In addition, MAthrombin, R time, MAadp and TEGaradp were also examined for determining HTPR. In conclusion, nMAadp and TEGaradp were demonstrated to be independent indicators for HTPR; nMAadp had the strongest power to identify HTPR with cutoff value of 26.3 mm; MAthrombin and R time were not significantly different between patients with and without HTPR; combination of TEGaradp and nMAadp further improved the ability to identify HTPR with an AUC of 0.893.<\/jats:p>","DOI":"10.1042\/bsr20201346","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T14:29:52Z","timestamp":1594218592000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients"],"prefix":"10.1042","volume":"40","author":[{"given":"Daye","family":"Cheng","sequence":"first","affiliation":[{"name":"Transfusion Department, First Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Transfusion Department, First Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-6349","authenticated-orcid":false,"given":"Yiwen","family":"Hao","sequence":"additional","affiliation":[{"name":"Transfusion Department, First Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2021111620205877100_B1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2021111620205877100_B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1586\/14779072.2.4.535","article-title":"Platelet activation in myocardial ischemic syndromes","volume":"2","author":"Gurbel","year":"2004","journal-title":"Exp. Rev. Cardiovasc. Ther."},{"key":"2021111620205877100_B3","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","article-title":"Platelet-Mediated Thrombosis: From Bench to Bedside","volume":"118","author":"Gurbel","year":"2016","journal-title":"Circ. Res."},{"key":"2021111620205877100_B4","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet (London, England)"},{"key":"2021111620205877100_B7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"2021111620205877100_B8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"2021111620205877100_B9","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021111620205877100_B10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B11","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","article-title":"Platelet function monitoring in patients with coronary artery disease","volume":"50","author":"Gurbel","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5482\/ha-1133","article-title":"Platelet function testing in clinical diagnostics","volume":"31","author":"Rechner","year":"2011","journal-title":"Hamostaseologie"},{"key":"2021111620205877100_B13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.jacc.2012.11.080","article-title":"Platelet function tests in clinical cardiology: unfulfilled expectations","volume":"61","author":"Gorog","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"2021111620205877100_B15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/09537104.2011.614974","article-title":"The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity","volume":"23","author":"Park","year":"2012","journal-title":"Platelets"},{"key":"2021111620205877100_B16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/FJC.0000000000000631","article-title":"Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay","volume":"73","author":"Polzin","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021111620205877100_B17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09537104.2018.1453058","article-title":"Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor","volume":"29","author":"Mingant","year":"2018","journal-title":"Platelets"},{"key":"2021111620205877100_B18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF01697545","article-title":"Blutgerinnungsstudien mit der thromboelastographie, einem neuen Untersuchungsverfahren","volume":"26","author":"Hartert","year":"1948","journal-title":"Klin Wochenschrif"},{"key":"2021111620205877100_B19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/ajcp\/aqz074","article-title":"The Utility of Thromboelastography to Guide Blood Product Transfusion","volume":"152","author":"Schmidt","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"2021111620205877100_B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jamcollsurg.2018.03.031","article-title":"Utility of Viscoelastic Assays Beyond Coagulation: Can Preoperative Thrombelastography Indices Predict Tumor Histology, Nodal Disease, and Resectability in Patients Undergoing Pancreatectomy?","volume":"227","author":"Moore","year":"2018","journal-title":"J. Am. Coll. Surg."},{"key":"2021111620205877100_B21","first-page":"e23224","article-title":"Establishment of thromboelastography reference intervals by indirect method and relevant factor analyses","volume":"2020","author":"Cheng","journal-title":"J. Clin. Lab. Anal."},{"key":"2021111620205877100_B22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/978-1-4939-7196-1_39","article-title":"Thromboelastography (TEG)","volume":"1646","author":"Othman","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"2021111620205877100_B23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.lab.2004.01.011","article-title":"A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation","volume":"143","author":"Craft","year":"2004","journal-title":"J. Lab. Clin. Med."},{"key":"2021111620205877100_B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1309\/AJCPQ9BYJ0OEENGA","article-title":"Platelet mapping assay interference due to platelet activation in heparinized samples","volume":"142","author":"Nelles","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"2021111620205877100_B25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jacc.2006.10.050","article-title":"Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?","volume":"49","author":"Bliden","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.thromres.2006.05.006","article-title":"Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting","volume":"119","author":"Gurbel","year":"2007","journal-title":"Thromb. Res."},{"key":"2021111620205877100_B27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","article-title":"Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events","volume":"160","author":"Gurbel","year":"2010","journal-title":"Am. Heart J."},{"key":"2021111620205877100_B28","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620205877100_B29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur. Heart J."},{"key":"2021111620205877100_B30","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1182\/blood-2006-12-027698","article-title":"The growing complexity of platelet aggregation","volume":"109","author":"Jackson","year":"2007","journal-title":"Blood"},{"key":"2021111620205877100_B31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Intervent."},{"key":"2021111620205877100_B32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet (London, England)"},{"key":"2021111620205877100_B33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4103\/0366-6999.152611","article-title":"Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel","volume":"128","author":"Tang","year":"2015","journal-title":"Chin. Med. J. (Engl.)"},{"key":"2021111620205877100_B34","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"2021111620205877100_B35","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidze","year":"2007","journal-title":"Eur. Heart J."},{"key":"2021111620205877100_B36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/09537104.2012.675108","article-title":"Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y (12) receptor inhibitors and high on-treatment platelet reactivity","volume":"24","author":"Jeong","year":"2013","journal-title":"Platelets"},{"key":"2021111620205877100_B37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41401-019-0278-9","article-title":"Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography","volume":"41","author":"Wu","year":"2020","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20201346\/888235\/bsr-2020-1346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20201346\/888235\/bsr-2020-1346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:51:50Z","timestamp":1637095910000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/7\/BSR20201346\/225736\/Net-platelet-clot-strength-of-thromboelastography"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20201346","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,7]]},"article-number":"BSR20201346"}}